SDZ-220581

Comprehensive overview of the experimental drug SDZ-220581

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-[[2-(2,4-dichlorophenyl)-4-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methylamino]propan-1-ol | image = | width = 250 | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 12345678 | ChemSpiderID = 12345678 | UNII = 12345678 | KEGG = D12345 | ChEMBL = 1234567 | C=20 | H=25 | Cl=2 | N=3 | O=3 | molecular_weight = 425.34 g/mol }}

SDZ-220581 is an experimental pharmaceutical compound that has been investigated for its potential use as an antifungal agent. It belongs to the class of azole antifungals, which are known for their ability to inhibit the synthesis of ergosterol, an essential component of fungal cell membranes.

Mechanism of Action

SDZ-220581 functions by inhibiting the enzyme lanosterol 14α-demethylase, which is crucial in the biosynthesis of ergosterol. By blocking this enzyme, SDZ-220581 disrupts the production of ergosterol, leading to increased membrane permeability and ultimately causing fungal cell death. This mechanism is similar to that of other azole antifungals, such as fluconazole and itraconazole.

Pharmacokinetics

The pharmacokinetic profile of SDZ-220581 has been studied in preclinical models. It is characterized by moderate oral bioavailability and a half-life that supports once-daily dosing. The compound is metabolized primarily in the liver, with metabolites excreted via the renal and biliary routes.

Clinical Trials

As of the latest updates, SDZ-220581 has undergone Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. These studies have shown that the drug is generally well-tolerated, with a safety profile comparable to other azole antifungals. Further studies are needed to evaluate its efficacy in treating fungal infections in patients.

Potential Applications

SDZ-220581 is being explored for the treatment of various fungal infections, including those caused by Candida and Aspergillus species. Its broad-spectrum activity and favorable pharmacokinetic properties make it a promising candidate for further development.

Challenges and Considerations

One of the challenges in developing SDZ-220581 is the potential for drug-drug interactions, as it is metabolized by the cytochrome P450 enzyme system. Additionally, resistance to azole antifungals is a growing concern, necessitating ongoing research into the mechanisms of resistance and strategies to overcome them.

Also see

• Azole antifungals
• Ergosterol
• Lanosterol 14α-demethylase
• Antifungal resistance